Combined taurine, epigallocatechin gallate and genistein therapy reduces HSC-T6 cell proliferation and modulates the expression of fibrogenic factors

International Journal of Molecular Sciences

Volumn 14, Issue 10, 2013, Pages 20543-20554

  Li, Yan ^a   Luo, Ying ^b   Zhang, Xuerong ^b   Lin, Xing ^b   He, Min ^b   Liao, Ming ^b  

^a GUANGXI UNIVERSITY   (China)

^b GUANGXI MEDICAL UNIVERSITY   (China)

Author keywords

Epigallocatechin gallate; Fibrosis related genes; Hepatic stellate cells; Liver fibrosis; Proteomics; Taurine

Indexed keywords

COLLAGEN TYPE 1; EPIGALLOCATECHIN GALLATE; GELATINASE A; GENISTEIN; MESSENGER RNA; TAURINE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TRANSFORMING GROWTH FACTOR BETA1;

ARTICLE; BIOLOGICAL ACTIVITY; CELL ACTIVATION; CELL ASSAY; CELL PROLIFERATION; CELL STRAIN; CELL STRAIN HSC T6; COL I GENE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; LIVER FIBROSIS; MMP 2 GENE; PROTEIN EXPRESSION; PROTEOMICS; STELLATE CELL; TGF BETA1 GENE; TIMP 1 GENE; TIMP 2 GENE;

ANIMALS; CATECHIN; CELL LINE; CELL PROLIFERATION; COLLAGEN TYPE I; DOWN-REGULATION; DRUG THERAPY, COMBINATION; GENISTEIN; LIVER CIRRHOSIS; MATRIX METALLOPROTEINASE 2; RATS; RNA, MESSENGER; TAURINE; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TISSUE INHIBITOR OF METALLOPROTEINASE-2; TRANSFORMING GROWTH FACTOR BETA1; UP-REGULATION;

EID: 84885935358     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms141020543     Document Type: Article

References (36)

1. Lee, U.E.; Friedman, S.L. Mechanisms of hepatic fibrogenesis. Best Pract. Res. Clin. Gastroenterol. 2011, 125, 195-206.
2. Friedman, S.L. Mechanisms of hepatic fibrogenesis. Gastroenterology 2008, 134, 1655-1669.
3. Bataller, R.; Brenner, D.A. Liver fibrosis. J. Clin. Invest. 2005, 115, 209-218.
4. Bonis, P.A.L.; Friedman, S.L.; Kaplan, M.M. Is liver fibrosis reversible? N. Engl. J. Med. 2001, 344, 452-454.
5. Distler, J.H.; Distler, O. Tyrosine kinase inhibitors for the treatment of fibrotic diseases such as systemic sclerosis: Towards molecular targeted therapies. Ann. Rheum. Dis. 2010, 69, i48-i51.
6. Sánchez-Valle, V.; Chávez-Tapia, N.C.; Uribe, M.; Méndez-Sánchez, N. Role of oxidative stress and molecular changes in liver fibrosis: A review. Curr. Med. Chem. 2012, 19, 4850-4860.
7. Campo, G.M.; Avenoso, A.; Campo, S.; D'Ascola, A.; Ferlazzo, A.M.; Calatroni, A. The antioxidant and antifibrogenic effects of the glycosaminoglycans hyaluronic acid and chondroitin-4-sulphate in a subchronic rat model of carbon tetrachloride-induced liver fibrogenesis. Chem. Biol. Interact. 2004, 148, 125-138.
8. Gebhardt, R. Oxidative stress, plant-derived antioxidants and liver fibrosis. Planta Med. 2002, 68, 289-296.
9. Carragher, N.O.; Unciti-Broceta, A.; Cameron, D.A. Advancing cancer drug discovery towards more agile development of targeted combination therapies. Future Med. Chem. 2012, 4, 87-105.
10. Kumar, M.; Sarin, S.K. Systematic review: Combination therapies for treatment-naïve chronic hepatitis B. Aliment. Pharmacol. Ther. 2008, 27, 1187-1209.
11. Chen, Y.X.; Zhang, X.R.; Xie, W.F.; Li, S. Effects of taurine on proliferation and apoptosis of hepatic stellate cells in vitro. Hepatobiliary Pancreat. Dis. Int. 2004, 3, 106-109.
12. Kato, J.; Ido, A.; Hasuike, S.; Uto, H.; Hori, T.; Hayashi, K.; Murakami, S.; Terano, A.; Tsubouchi, H. Transforming growth factor-β-induced stimulation of formation of collagen fiber network and antifibrotic effect of taurine in an in vitro model of hepatic fibrosis. Hepatol. Res. 2004, 30, 34-41.
13. Miyazaki, T.; Karube, M.; Matsuzaki, Y.; Ikegami, T.; Doy, M.; Tanaka, N.; Bouscarel, B. Taurine inhibits oxidative damage and prevents fibrosis in carbon tetrachloride-induced hepatic fibrosis. J. Hepatol. 2005, 43, 117-125.
14. Nakamuta, M.; Higashi, N.; Kohjima, M.; Fukushima, M.; Ohta, S.; Kotoh, K.; Kobayashi, N.; Enjoji, M. Epigallocatechin-3-gallate, a polyphenol component of green tea, suppresses both collagen production and collagenase activity in hepatic stellate cells. Int. J. Mol. Med. 2005, 27, 677-681.
15. Liu, X.; Huang, M.; Cheng, N.; Xiao, W.; Wang, Y. Effects of genistein on the fenestrae, proliferation and nitric oxide synthesis of liver sinusoidal endothelial cells from carbon tetrachloride-induced experimental hepatic fibrosis rats. Zhonghua Gan Zang Bing Za Zhi 2002, 10, 200-203.
16. Lang, Zh.; Liao, M.; Zheng, Li.; He, M.; Huang, Ch.F.; Zhang, S.; Lin, X. Combination therapy with taurine, epigallocatechin gallate and genistein for protection against hepatic fibrosis induced by alcohol in rat. Biol. Pharm. Bull. 2012, 35, 1802-1810.
17. Friedman, S.L. Hepatic stellate cells: Protean, multifunctional, and enigmatic cells of the liver. Physiol. Rev. 2008, 88, 125-172.
18. Wu, J.; Zern, M.A. Hepatic stellate cells: A target for the treatment of liver fibrosis. J. Gastroenterol. 2000, 35, 665-672.
19. Lotersztajn, S.; Julien, B.; Teixeira-Clerc, F.; Grenard, P.; Mallat, A. Hepatic fibrosis: Molecular mechanisms and drug targets. Annu. Rev. Pharmacol. Toxicol. 2005, 45, 605-628.
20. Hernandez-Gea, V.; Friedman, S.L. Pathogenesis of liver fibrosis. Annu. Rev. Pathol. 2011, 6, 425-456.
21. Gressner, A.M.; Weiskirchen, R.; Breitkopf, K.; Dooley, S. Roles of TGF-beta in hepatic fibrosis. Front. Biosci. 2002, 7, d793-d807.
22. Bauer, M.; Schuppan, D. TGF beta1 in liver fibrosis: Time to change paradigms? FEBS. Lett. 2001, 502, 1-3.
23. Shek, F.W.; Benyon, R.C. How can transforming growth factor beta be targeted usefully to combat liverfibrosis? Eur. J. Gastroenterol. Hepatol. 2004, 16, 123-126.
24. Brew, K.; Dinakarpandian, D.; Nagase, H. Tissue inhibitors of metalloproteinases: Evolution, structure and function. Biochim. Biophys. Acta 2000, 477, 267-283.
25. Yoshiji, H.; Kuriyama, S.; Yoshii, J.; Ikenaka, Y.; Noguchi, R.; Nakatani, T.; Tsujinoue, H.; Yanase, K.; Namisaki, T.; Imazu, H.; et al. Tissue inhibitor of metalloproteinases-1 attenuates spontaneous liver fibrosis resolution in the transgenic mouse. Hepatology 2002, 36, 850-860.
26. Yoshiji, H.; Kuriyama, S.; Miyamoto, Y.; Thorgeirsson, U.P.; Gomez, D.E.; Kawata, M.; Yoshii, J.; Ikenaka, Y.; Noguchi, R.; Tsujinoue, H.; et al. Tissue inhibitor of metalloproteinases-1 promotes liver fibrosis development in a transgenic mouse model. Hepatology 2000, 32, 1248-1254.
27. Hayasaka, A.; Suzuki, N.; Fujimoto, N.; Iwama, S.; Fukuyama, E.; Kanda, Y.; Saisho, H. Elevated plasma levels of matrix metalloproteinase-9 (92-kd type IV collagenase/gelatinase B) in hepatocellular carcinoma. Hepatology 1996, 24, 1058-1062.
28. Takahara, T.; Furui, K.; Funaki, J.; Nakayama, Y.; Itoh, H.; Miyabayashi, C.; Sato, H.; Seiki, M.; Ooshima, A.; Watanabe, A. Increased expression of matrix metalloproteinase-II in experimental liver fibrosis in rats. Hepatology 1995, 21, 787-795.
29. Gressner, A.M. The cell biology of liver fibrogenesis-an imbalance of proliferation, growth arrest and apoptosis of myofibroblasts. Cell Tissue Res. 1998, 292, 447-452.
30. Friedman, S.L. Cellular sources of collagen and regulation of collagen production in liver. Semin. Liver Dis. 1990, 10, 20-29.
31. Adam, C.; Hans, L.; Åke, L. The evolution of a genetic locus encoding small serine proteinase inhibitors. Biochem. Biophys. Res. Commun. 2005, 333, 383-389.
32. Al-Gubory, K.H.; Huet, J.C.; Pernollet, J.C.; Martal, J.; Locatelli, A. Corpus luteum derived copper, zinc-superoxide dismutase serves as a luteinizing hormone-release inhibiting factor in sheep. Mol. Cell. Endocrinol. 2003, 199, 1-9.
33. Hwan, J.C.; Freeman, M.E. A physiological role for luteinizing hormone release-inhibiting factor of hypothalamic origin. Endocrinology 1987, 121, 1099-1103.
34. Hegeman, A.D.; Brown, J.S.; Lomax, M.I. Sequence of the cDNA for the heart/muscle isoform of mouse cytochrome c oxidase subunit VIII. Biochim. Biophys. Acta 1995, 1261, 311-314.
35. Chusho, H.; Tamura, N.; Ogawa, Y.; Yasoda, A.; Suda, M.; Miyabayashi, C.; Sato, H.; Seiki, M.; Ooshima, A.; Watanabe, A. Dwarfism and early death in mice lacking C-type natriuretic peptide. Proc. Natl. Acad. Sci. USA 2001, 98, 4016-4021.
36. Madhani, M.; Scotland, R.S.; MacAllister, R.J.; Hobbs, A.J. Vascular natriuretic peptide receptor-linked particulate guanylate cyclases are modulated by nitric oxide-cyclic GMP signalling. Br. J. Pharmacol. 2003, 139, 1289-1296.